Whole-Tumor ADC Texture Analysis Is Able to Predict Breast Cancer Receptor Status.
ADC
breast cancer
prediction
radiomics
receptor
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
14 Apr 2023
14 Apr 2023
Historique:
received:
12
03
2023
revised:
04
04
2023
accepted:
11
04
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
There are different breast cancer molecular subtypes with differences in incidence, treatment response and outcome. They are roughly divided into estrogen and progesterone receptor (ER and PR) negative and positive cancers. In this retrospective study, we included 185 patients augmented with 25 SMOTE patients and divided them into two groups: the training group consisted of 150 patients and the validation cohort consisted of 60 patients. Tumors were manually delineated and whole-volume tumor segmentation was used to extract first-order radiomic features. The ADC-based radiomics model reached an AUC of 0.81 in the training cohort and was confirmed in the validation set, which yielded an AUC of 0.93, in differentiating ER/PR positive from ER/PR negative status. We also tested a combined model using radiomics data together with ki67% proliferation index and histological grade, and obtained a higher AUC of 0.93, which was also confirmed in the validation group. In conclusion, whole-volume ADC texture analysis is able to predict hormonal status in breast cancer masses.
Identifiants
pubmed: 37189515
pii: diagnostics13081414
doi: 10.3390/diagnostics13081414
pmc: PMC10137680
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Magn Reson Imaging. 2019 Sep;50(3):836-846
pubmed: 30811717
Proteins. 2008 Mar;70(4):1125-32
pubmed: 18076026
Breast Cancer (Auckl). 2022 Apr 19;16:11782234221092155
pubmed: 35462754
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Mol Imaging Biol. 2020 Jun;22(3):780-787
pubmed: 31463822
Medicina (Kaunas). 2022 Nov 23;58(12):
pubmed: 36556918
Magn Reson Imaging. 2018 Dec;54:176-182
pubmed: 30172938
Am J Clin Pathol. 2002 May;117(5):723-8
pubmed: 12090420
Medicine (Baltimore). 2021 Jun 4;100(22):e25878
pubmed: 34087829
BMC Med Inform Decis Mak. 2013 Nov 09;13:124
pubmed: 24207108
Eur Radiol. 2022 Jul;32(7):4834-4844
pubmed: 35094119
Molecules. 2020 Jan 15;25(2):
pubmed: 31952272
In Vivo. 2022 Jan-Feb;36(1):398-408
pubmed: 34972741
NMR Biomed. 2018 Feb;31(2):
pubmed: 29244222
BMC Med Imaging. 2017 Dec 29;17(1):69
pubmed: 29284425
J Magn Reson Imaging. 2015 Oct;42(4):902-7
pubmed: 25777181
NPJ Breast Cancer. 2016;2:
pubmed: 27853751
Diagnostics (Basel). 2022 Oct 21;12(10):
pubmed: 36292247
Mol Imaging Biol. 2020 Apr;22(2):453-461
pubmed: 31209778
Cancer Manag Res. 2019 Sep 06;11:8239-8247
pubmed: 31564982
Invest Radiol. 2017 Jun;52(6):317-323
pubmed: 28368880
Cancers (Basel). 2022 Nov 09;14(22):
pubmed: 36428600
Cancer Treat Rev. 2014 Feb;40(1):129-38
pubmed: 23891266
Acad Radiol. 2022 Aug;29(8):1228-1247
pubmed: 34799256
Front Oncol. 2021 Sep 16;11:628824
pubmed: 34604024
Biomed Res Int. 2021 Jun 24;2021:4970265
pubmed: 34258262
Diagnostics (Basel). 2020 Sep 17;10(9):
pubmed: 32957690
Radiology. 2014 Nov;273(2):365-72
pubmed: 25028781
Eur Radiol. 2020 Jan;30(1):66-76
pubmed: 31385051
J Cancer Res Clin Oncol. 2019 Dec;145(12):2983-2994
pubmed: 31628534
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
Contrast Media Mol Imaging. 2019 Nov 22;2019:2972189
pubmed: 31819738